This trial is evaluating whether Pembrolizumab will improve 2 primary outcomes and 11 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to ~ 51 months.
This trial requires 1240 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
Men suffering prostate cancer are at a high risk of dying from heart disease and stroke. It is therefore important that primary care physicians keep an eye out for signs of cardiovascular disease in their patients. Diabetes and hypertension can also be associated with an increased risk of prostate cancer.
This article highlights the important, yet inconclusive, research available about possible cures for prostate cancer. However, in the short term, many men are still living with a prostate cancer diagnosis, and a cure is desperately needed.
Different approaches are used depending on the type and progression severity of the disease. The current status of cancer in the United States is an improving one. New and exciting therapies have helped in increasing the survival rates especially in advanced cancer stages. Radiation and surgery are the standard of care for most prostate cancer. Many types of medications have been used against prostate cancer such that a treatment plan has to be generated based on the disease, the patient, and the health professionals. New medications and therapies have been approved to help prostate cancer patients. It is crucial for health professionals involved in managing the cancers, especially through cancer and its related subtypes, to keep up to date and be updated on newer cancer treatments.
At least 25 million US residents were diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in 2000. This leads to an average of 11,000 diagnoses a year. It is also estimated that 10% of these men will have one metastatic bone disease and 50% will have one primary cancer. As such, prostate cancer remains the most common cancer diagnosed in the United States in 2000.
Mean average age at time of diagnosis for prostate cancer is 66.4 ±13.2. The incidence of prostate cancer is highest in a narrow age span at 61.4–67.2. Age at diagnosis is not prognostically significant. A decrease of age at diagnosis will not solve the problem of prostate cancer as a major public health problem.
Given pembrolizumab is approved for treatment of cancer metastatic to the brain, skin and lymph nodes, it can be administered safely to people with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), as was previously found in randomized phase II or multicenter clinical trials. Prostate biopsies can be done with or without MRI as they are of no importance for treatment response.
At 4 and 8 years, the 5 year survival rate for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is about 77%. The survival rate over 10 years is still 60-65%. The survival rate for prostate cancer is much lower in patients who present with prostate cancer at high volume disease (i.e., cancer in half of the prostate) or more advanced stage than high volume cancer (stage T3b or higher). Prostate cancer with these higher-risk features presents many technical challenges to treatment that requires careful consideration of the risk versus the benefit.
Clinicians and men should consider a clinical trial when they have concerns about disease burden or treatment options. The use of a clinical trial is associated with positive mood. The use of a clinical trial appears to reduce men's thoughts about prostate cancer.
Pembrolizumab has been approved by the FDA and EMA as a treatment of melanoma (among others). Its use for other cancer indications is under investigation. Pembrolizumab is currently used in conjunction with other anticancer agents for treating patients with the following diseases: melanoma, metastatic renal cell carcinoma, advanced non-small cell lung cancer, triple negative breast cancer, colorectal cancer, and in relapsed advanced solid tumours. The drug acts by antagonizing PD-1, a receptor found primarily in tumour cells but rarely in normal cells. This property has created opportunities for cancer immunotherapy, which entails manipulating immune systems to detect and kill cancer cells.
The association of environmental exposures with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is not entirely clear. The contribution of these factors is not completely understood, although most likely they are complex and act simultaneously in the biologic pathways of cancer initiation and promotion.